@BioTechHealthX BioTech Health X
BioTech Health X posts on X about health, nasdaq, stocks, market the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [-----] +42%
- [--] Month [------] -1.40%
- [--] Months [------] +224%
- [--] Year [------] +6,883%
Mentions: [--] #
- [--] Week [--] +7.10%
- [--] Month [--] +19%
- [--] Months [---] +457%
- [--] Year [---] +10,875%
Followers: [---] #
- [--] Week [---] +1.90%
- [--] Month [---] +3.80%
- [--] Months [---] +22%
- [--] Year [---] +46%
CreatorRank: [---------] #
Social Influence
Social category influence stocks 56.19% finance 35.24% exchanges #5198 cryptocurrencies 6.67% technology brands 2.86% currencies 0.95%
Social topic influence health 97.14%, nasdaq #764, stocks 14.29%, market 7.62%, strong 7.62%, future 4.76%, the most 4.76%, science 3.81%, longterm 3.81%, company 3.81%
Top accounts mentioned or mentioned by @kyvernatx @axsome @achievelifesci @dbvtechnologies @mindmedicineau @moleculinbio @unicycive @niagenbio @iovancebio @instilbio @monterosatx @calcimedicainc @exelixisinc @aviditybio @cgoncology @4dmolecular @unitedhealthgrp @immixbiopharma @elevancehealth @mckesson
Top assets mentioned Ocular Therapeutix, Inc. (OCUL) Prelude Therapeutics Inc. (PRLD) Candel Therapeutics, Inc. (CADL) Muhdo Hub (DNA) AbCellera Biologics Inc. (ABCL) Allora (ALLO) Iovance Biotherapeutics, Inc. Common Stock (IOVA) PMV Pharmaceuticals, Inc. (PMVP) Context Therapeutics Inc. (CNTX) Nuvation Bio Inc. (NUVB) Nkarta, Inc. (NKTX) Kyverna Therapeutics, Inc. (KYTX) UnitedHealth Group (UNH) Immix Biopharma, Inc. (IMMX) Turn Therapeutics, Inc. (TTRX) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Axsome Therapeutics, Inc (AXSM) Unicycive Therapeutics, Inc. (UNCY) Atea Pharmaceuticals, Inc. (AVIR) Instil Bio, Inc. (TIL) Monte Rosa Therapeutics, Inc. (GLUE) CalciMedica, Inc. (CALC) Oric Pharmaceuticals, Inc. (ORIC) Cullinan Management, Inc. (CGEM) Exelixis Inc (EXEL) Avidity Biosciences, Inc. (RNA) CG Oncology, Inc. (CGON) 4D Molecular Therapeutics Inc. (FDMT) Elevance Health Inc (ELV) Abbott Laboratories (ABT) Intuitive Surgical, Inc. (ISRG) Measurable Data Token (MDT) Arcblock (ABT) Johnson & Johnson (JNJ) McKesson Corporation (MCK)
Top Social Posts
Top posts by engagements in the last [--] hours
"$DNA $AEMD $ABCL $SXTC $THAR $PLSE $CANF $TOI $GRI $PRLD Biotech stocks often surge on news tied to clinical progress and regulatory updates. Learn why breakthroughs in drug discovery genetics and AI are translating into rapid price action across the sector today. https://biotechhealthx.com/biotech-news/top-10-biotech-stocks-with-the-biggest-price-gains-today/ https://biotechhealthx.com/biotech-news/top-10-biotech-stocks-with-the-biggest-price-gains-today/"
X Link 2026-02-06T10:53Z [---] followers, [---] engagements
"$CMPX Compass Therapeutics (NASDAQ:CMPX) is on biotech watchlists as oncology data and upcoming catalysts drive interest. Heres what investors are watching why the setup matters and where risk lives. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-acquire-compass-therapeutics-cmpx-shares/ https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-acquire-compass-therapeutics-cmpx-shares/"
X Link 2026-02-08T17:07Z [---] followers, [---] engagements
"$AVTX Avalo Therapeutics (NASDAQ:AVTX) is heading toward a high-stakes Phase [--] LOTUS readout in hidradenitis suppurativa and the market loves a clean biotech catalyst. Heres why AVTX stock could reprice fast if AVTX-009 delivers real efficacy and a workable safety profile. https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtxs-next-5-minutes-of-fame-the-hs-data-drop-that-could-shock-traders/ https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtxs-next-5-minutes-of-fame-the-hs-data-drop-that-could-shock-traders/"
X Link 2026-02-12T17:09Z [---] followers, [---] engagements
"$ALLO $VSTM $IOVA $CMPX $PMVP $CADL $CNTX $NKTX $ONCY $NUVB Cancer biotech stocks can stay silent for monthsthen surge overnight when a trial hits its primary endpoint. Discover the [--] oncology small-caps with catalyst calendars clinical milestones and asymmetric upside that could reshape market sentiment in [----]. https://biotechhealthx.com/biotech-news/top-10-cancer-biotech-small-caps-that-could-shock-the-market-next/ https://biotechhealthx.com/biotech-news/top-10-cancer-biotech-small-caps-that-could-shock-the-market-next/"
X Link 2026-02-14T04:13Z [---] followers, [---] engagements
"$IOVA Real-world outcomes can make or break a biotech launch and Iovance is putting numbers on the board. Learn what the latest advanced melanoma data suggests about Amtagvi why treatment timing matters and how expanding treatment centers and manufacturing could unlock the next leg for @IovanceBio. https://biotechhealthx.com/biotech-news/44-real-world-response-iovance-iova-just-made-off-the-bench-data-the-new-headline/ https://biotechhealthx.com/biotech-news/44-real-world-response-iovance-iova-just-made-off-the-bench-data-the-new-headline/"
X Link 2026-02-14T04:16Z [---] followers, [---] engagements
"$AVIR Atea Pharmaceuticals Inc (NASDAQ:AVIR) has completed enrollment in a major Phase [--] hepatitis C trial setting the stage for pivotal mid-2026 data that could reshape the antiviral treatment landscape. https://biotechhealthx.com/biotech-news/why-atea-pharmaceuticals-inc-avir-could-be-entering-its-most-important-phase-yet/ https://biotechhealthx.com/biotech-news/why-atea-pharmaceuticals-inc-avir-could-be-entering-its-most-important-phase-yet/"
X Link 2025-12-24T05:08Z [---] followers, [---] engagements
"$PRLD Prelude Therapeutics Incorporated (NASDAQ:PRLD) is leveraging targeted protein degradation and next generation discovery to design novel precision cancer medicines. This article explores Prelude Therapeutics origins strategy and why the companys clinical development direction is getting new attention across precision oncology investing. https://biotechhealthx.com/biotech-news/is-prelude-therapeutics-prld-the-next-precision-medicine-breakout/ https://biotechhealthx.com/biotech-news/is-prelude-therapeutics-prld-the-next-precision-medicine-breakout/"
X Link 2025-12-28T00:13Z [---] followers, [---] engagements
"$TIL @InstilBio Inc (NASDAQ:TIL) recently restructured its development focus and the implications could be far bigger than the headlines suggest. Heres what this strategic reset really means for the future of the company and its stock. https://biotechhealthx.com/biotech-news/instil-bio-inc-nasdaqtil-just-reset-its-strategy-and-that-could-change-everything/ https://biotechhealthx.com/biotech-news/instil-bio-inc-nasdaqtil-just-reset-its-strategy-and-that-could-change-everything/"
X Link 2026-01-06T14:30Z [---] followers, [---] engagements
"$GLUE With its molecular glue degrader platform @MonteRosaTx (NASDAQ: GLUE) is working on therapies designed to eliminate disease-causing proteins rather than just inhibit them. Discover what makes GLUE stock a unique biotech opportunity. https://biotechhealthx.com/biotech-news/monte-rosa-therapeutics-glue-is-targeting-diseases-other-drugs-cant-touch/ https://biotechhealthx.com/biotech-news/monte-rosa-therapeutics-glue-is-targeting-diseases-other-drugs-cant-touch/"
X Link 2026-01-07T14:14Z [---] followers, [--] engagements
"$CALC @CalciMedicaInc (NASDAQ:CALC) isnt chasing crowded drug trends. Its going after calcium signaling in inflammationand that focus could define its future. https://biotechhealthx.com/biotech-news/calcimedica-calc-high-risk-biotech-or-deep-science-sleeper/ https://biotechhealthx.com/biotech-news/calcimedica-calc-high-risk-biotech-or-deep-science-sleeper/"
X Link 2026-01-18T18:01Z [---] followers, [---] engagements
"$ORIC With short interest climbing and analysts staying bullish ORIC Pharmaceuticals sits at the center of a rare biotech disconnect. We break down what the market sees and what it may be ignoring. https://biotechhealthx.com/biotech-news/23-of-traders-are-short-this-oncology-stock-heres-what-they-might-be-missing-about-oric-pharma-oric/ https://biotechhealthx.com/biotech-news/23-of-traders-are-short-this-oncology-stock-heres-what-they-might-be-missing-about-oric-pharma-oric/"
X Link 2026-01-23T17:17Z [---] followers, [--] engagements
"$CGEM As clinical data matures and regulatory milestones approach Cullinan Therapeutics Inc. (NASDAQ: CGEM) may transition from a cash-burn narrative to a value-creation story. https://biotechhealthx.com/biotech-news/cullinan-therapeutics-cgem-could-be-the-biotech-stock-the-market-mispriced/ https://biotechhealthx.com/biotech-news/cullinan-therapeutics-cgem-could-be-the-biotech-stock-the-market-mispriced/"
X Link 2026-01-23T17:34Z [---] followers, [---] engagements
"$EXEL While hype-driven biotech stocks burn cash @ExelixisInc stock keeps delivering real oncology revenue. Heres why NASDAQ: EXEL is quietly becoming a long-term winner. https://biotechhealthx.com/biotech-news/exelixis-exel-isnt-a-flashy-biotech-its-the-one-quietly-making-billions/ https://biotechhealthx.com/biotech-news/exelixis-exel-isnt-a-flashy-biotech-its-the-one-quietly-making-billions/"
X Link 2026-01-23T17:48Z [---] followers, [---] engagements
"$RNA @aviditybio (NASDAQ:RNA) is still unprofitable yet the stock continues to surge. Heres why the market may be betting on its antibody-oligonucleotide conjugate platform over short-term earnings. https://biotechhealthx.com/biotech-news/heres-why-avidity-biosciences-rna-keeps-hitting-new-highs-despite-being-unprofitable/ https://biotechhealthx.com/biotech-news/heres-why-avidity-biosciences-rna-keeps-hitting-new-highs-despite-being-unprofitable/"
X Link 2026-01-23T17:49Z [---] followers, [--] engagements
"$KYTX @Kyverna_Tx (NASDAQ:KYTX) isnt chasing hype its chasing immune reset. Discover why this biotech stock is emerging as a leader in autoimmune CAR-T therapy. https://biotechhealthx.com/biotech-news/kyverna-therapeutics-kytx-is-being-called-the-autoimmune-car-t-pioneer/ https://biotechhealthx.com/biotech-news/kyverna-therapeutics-kytx-is-being-called-the-autoimmune-car-t-pioneer/"
X Link 2026-01-25T16:42Z [---] followers, [--] engagements
"$CGON @cgoncology (NASDAQ:CGON) is quietly emerging as one of the most talked-about biotech stocks in oncology. From its focused bladder cancer mission to its growing investor attention heres why CGON is landing on watchlists everywhere. https://biotechhealthx.com/biotech-news/is-this-the-next-breakout-biotech-why-cg-oncology-cgon-is-suddenly-on-smart-investors-radar/ https://biotechhealthx.com/biotech-news/is-this-the-next-breakout-biotech-why-cg-oncology-cgon-is-suddenly-on-smart-investors-radar/"
X Link 2026-01-25T16:43Z [---] followers, [---] engagements
"$FDMT @4DMolecular (NASDAQ:FDMT) is sitting on a massive cash runway while advancing gene therapy trials. FDMT stock however suggests the market isnt convinced yetand that tension is getting interesting. https://biotechhealthx.com/biotech-news/this-biotech-has-more-cash-than-confidence-meet-4d-molecular-therapeutics-inc-nasdaqfdmt/ https://biotechhealthx.com/biotech-news/this-biotech-has-more-cash-than-confidence-meet-4d-molecular-therapeutics-inc-nasdaqfdmt/"
X Link 2026-01-25T16:47Z [---] followers, [---] engagements
"$UNH @UnitedHealthGrp Incorporated (NYSE: UNH) adapts to regulatory shifts and cost pressures through scale technology and value-based care making it a cornerstone stock in healthcare investing. https://biotechhealthx.com/biotech-news/heres-why-unitedhealth-group-unh-keeps-winning-while-healthcare-keeps-changing/ https://biotechhealthx.com/biotech-news/heres-why-unitedhealth-group-unh-keeps-winning-while-healthcare-keeps-changing/"
X Link 2026-01-28T16:20Z [---] followers, [---] engagements
"$IMMX @Immixbiopharma (NASDAQ: IMMX) is developing a novel CAR-T therapy for AL Amyloidosis a rare but deadly disease with no approved treatments. Heres the story behind the science. https://biotechhealthx.com/biotech-news/this-nasdaq-biotech-is-targeting-a-6-billion-market-no-one-talks-about-meet-immix-biopharma-immx/ https://biotechhealthx.com/biotech-news/this-nasdaq-biotech-is-targeting-a-6-billion-market-no-one-talks-about-meet-immix-biopharma-immx/"
X Link 2026-01-28T16:21Z [---] followers, [--] engagements
"$ELV @ElevanceHealth (NYSE: ELV) is deeply embedded in U.S. healthcare from Medicaid to Medicare Advantage. This article explores why ELV stock remains a sleeper giant in the market. https://biotechhealthx.com/biotech-news/elevance-health-elv-touches-millions-every-day-yet-it-rarely-makes-headlines/ https://biotechhealthx.com/biotech-news/elevance-health-elv-touches-millions-every-day-yet-it-rarely-makes-headlines/"
X Link 2026-01-28T16:37Z [---] followers, [--] engagements
"$ABT $UNH $JNJ $ISRG $MDT From Abbott Laboratories (NYSE:ABT) to UnitedHealth Group (NYSE:UNH) and Johnson & Johnson (NYSE:JNJ) healthcare companies continue to benefit from non-discretionary demand aging populations and innovation-driven growth. https://biotechhealthx.com/biotech-news/heres-why-healthcare-equipment-and-services-keep-winning-even-when-markets-panic/ https://biotechhealthx.com/biotech-news/heres-why-healthcare-equipment-and-services-keep-winning-even-when-markets-panic/"
X Link 2026-01-29T15:05Z [---] followers, [---] engagements
"$MCK With consistent revenue growth massive free cash flow and favorable analyst sentiment @McKesson Corporation (NYSE:MCK) is emerging as a compelling healthcare investment opportunity. https://biotechhealthx.com/biotech-news/wall-street-sees-nearly-15-upside-in-mckesson-corporation-mck-heres-why/ https://biotechhealthx.com/biotech-news/wall-street-sees-nearly-15-upside-in-mckesson-corporation-mck-heres-why/"
X Link 2026-01-31T15:47Z [---] followers, [--] engagements
"$MOH Investor expectations for Medicare Advantage rates triggered a sector-wide sell-off yet Molina Healthcare (NYSE:MOH) remains deeply embedded in government-sponsored healthcare programs with long-term demand visibility. https://biotechhealthx.com/biotech-news/healthcare-stocks-sold-off-fast-but-molina-healthcare-moh-may-be-misunderstood/ https://biotechhealthx.com/biotech-news/healthcare-stocks-sold-off-fast-but-molina-healthcare-moh-may-be-misunderstood/"
X Link 2026-01-31T15:48Z [---] followers, [---] engagements
"$PRLD Prelude Therapeutics surged after the FDA cleared its IND for PRT12396 a mutant-selective JAK2 inhibitor targeting high-risk blood cancers. We explain why this regulatory milestone could reshape PRLDs clinical trajectory and investor sentiment. https://biotechhealthx.com/biotech-news/is-it-a-wise-choice-to-invest-in-prelude-therapeutics-prld/ https://biotechhealthx.com/biotech-news/is-it-a-wise-choice-to-invest-in-prelude-therapeutics-prld/"
X Link 2026-02-06T11:25Z [---] followers, [--] engagements
"$IBRX @ImmunityBio (NASDAQ:IBRX) is drawing attention as its immunotherapy story gains real-world traction. We break down whats driving the buzz the growth outlook and the biggest risks investors need to know. https://biotechhealthx.com/biotech-news/is-it-still-worthy-to-buy-immunitybio-ibrx-shares/ https://biotechhealthx.com/biotech-news/is-it-still-worthy-to-buy-immunitybio-ibrx-shares/"
X Link 2026-02-08T17:06Z [---] followers, [----] engagements
"$TTRX Turn Therapeutics earns national recognition as one of the Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment. Learn how the GX-03 IL-36targeting technology could disrupt the $20B eczema market ahead of [----] topline data. https://biotechhealthx.com/biotech-news/turn-therapeutics-ttrx-named-top-innovator-in-atopic-dermatitis-with-gx-03-breakthrough/ https://biotechhealthx.com/biotech-news/turn-therapeutics-ttrx-named-top-innovator-in-atopic-dermatitis-with-gx-03-breakthrough/"
X Link 2025-11-24T04:09Z [---] followers, [---] engagements
"$SLNO Soleno Therapeutics Inc (NASDAQ:SLNO) is focused on precision therapies for rare diseases. This article explains why SLNOs long-term story might be more important than it looks. https://biotechhealthx.com/biotech-news/soleno-therapeutics-slno-might-be-building-something-bigger-than-most-investors-realize/ https://biotechhealthx.com/biotech-news/soleno-therapeutics-slno-might-be-building-something-bigger-than-most-investors-realize/"
X Link 2026-01-13T16:55Z [---] followers, [---] engagements
"$MDGL Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) has gone from overlooked to must-watch. Heres what makes its background and strategy different from typical biotech plays. https://biotechhealthx.com/biotech-news/why-madrigal-pharmaceuticals-mdgl-is-suddenly-on-every-biotech-watchlist/ https://biotechhealthx.com/biotech-news/why-madrigal-pharmaceuticals-mdgl-is-suddenly-on-every-biotech-watchlist/"
X Link 2026-01-18T17:38Z [---] followers, [---] engagements
"$AXSM @axsome Therapeutics Inc. (NASDAQ:AXSM) built its business around CNS disorders that big pharma abandoned and that contrarian focus may be exactly why its growth story keeps surprising investors. https://biotechhealthx.com/biotech-news/why-axsome-therapeutics-axsm-keeps-winning-in-a-part-of-pharma-everyone-else-quit/ https://biotechhealthx.com/biotech-news/why-axsome-therapeutics-axsm-keeps-winning-in-a-part-of-pharma-everyone-else-quit/"
X Link 2026-01-18T18:00Z [---] followers, [---] engagements
"$LEGN With expanding @FDA approvals growing manufacturing capacity and strong pharma partnerships @LegendBiotech Corporation (NASDAQ:LEGN) stands out as a high-quality CAR-T company with durable competitive advantages. https://biotechhealthx.com/biotech-news/legend-biotech-legn-could-be-one-of-the-smartest-car-t-bets-in-biotech-right-now/ https://biotechhealthx.com/biotech-news/legend-biotech-legn-could-be-one-of-the-smartest-car-t-bets-in-biotech-right-now/"
X Link 2026-01-23T17:16Z [---] followers, [---] engagements
"$HRMY As most biotech stocks burn cash Harmony Biosciences continues to grow revenue and profits. Discover what makes NASDAQ: HRMY one of the sectors quiet outperformers. https://biotechhealthx.com/biotech-news/harmony-biosciences-hrmy-keeps-beating-expectations-while-biotech-struggles/ https://biotechhealthx.com/biotech-news/harmony-biosciences-hrmy-keeps-beating-expectations-while-biotech-struggles/"
X Link 2026-01-23T17:34Z [---] followers, [--] engagements
"$MDGL Madrigal Pharmaceuticals stock didnt surge by accident. Behind the scenes was a long patient journey through metabolic liver disease research that few biotech companies were willing to endure. https://biotechhealthx.com/biotech-news/why-madrigal-pharma-mdgl-looks-like-an-overnight-success-after-years-of-relentless-science/ https://biotechhealthx.com/biotech-news/why-madrigal-pharma-mdgl-looks-like-an-overnight-success-after-years-of-relentless-science/"
X Link 2026-01-23T17:35Z [---] followers, [---] engagements
"$CING @CingulateInc (NASDAQ:CING) is racing toward a key FDA decision for its ADHD drug but rising cash burn and dilution risks raise tough questions. Is CING stock a breakthrough story or a financial cliff https://biotechhealthx.com/biotech-news/cingulate-cing-is-betting-big-on-adhd-but-is-it-running-out-of-time/ https://biotechhealthx.com/biotech-news/cingulate-cing-is-betting-big-on-adhd-but-is-it-running-out-of-time/"
X Link 2026-01-28T16:21Z [---] followers, [---] engagements
"$HUM @Humana Inc (NYSE:HUM) evolved from hospital ownership into a Medicare Advantage leader positioning itself at the center of U.S. healthcare insurance and value-based care. https://biotechhealthx.com/biotech-news/from-hospitals-to-medicare-dominance-how-humana-hum-built-a-healthcare-empire/ https://biotechhealthx.com/biotech-news/from-hospitals-to-medicare-dominance-how-humana-hum-built-a-healthcare-empire/"
X Link 2026-01-28T16:36Z [---] followers, [---] engagements
"$TEVA Teva Pharmaceutical Industries Limited (NYSE: TEVA) is reinventing itself with a powerful mix of generics specialty drugs and biosimilars. After years of restructuring this pharma stock is drawing fresh investor attention. https://biotechhealthx.com/biotech-news/this-120-year-old-pharma-giant-is-suddenly-hot-again-teva-pharmaceutical-teva/ https://biotechhealthx.com/biotech-news/this-120-year-old-pharma-giant-is-suddenly-hot-again-teva-pharmaceutical-teva/"
X Link 2026-01-28T16:36Z [---] followers, [--] engagements
"$HCA Raised price targets solid EBITDA performance and disciplined expense management are reshaping the investment case for @HCAhealthcare (NYSE:HCA). https://biotechhealthx.com/biotech-news/hca-healthcare-hca-is-acting-like-a-defensive-growth-stock-and-analysts-agree/ https://biotechhealthx.com/biotech-news/hca-healthcare-hca-is-acting-like-a-defensive-growth-stock-and-analysts-agree/"
X Link 2026-01-31T15:47Z [---] followers, [--] engagements
"$CANF @CanFitePharma (NYSE:CANF) reported a real-world case where its oral drug Namodenoson stabilized a critically ill liver patient long enough for a successful transplant. Could this overlooked biotech be sitting on a high-impact medical breakthrough the market hasnt priced in yet https://biotechhealthx.com/biotech-news/is-it-a-great-time-to-buy-can-fite-biopharma-canf-shares/ https://biotechhealthx.com/biotech-news/is-it-a-great-time-to-buy-can-fite-biopharma-canf-shares/"
X Link 2026-02-06T11:26Z [---] followers, [--] engagements
"$ABCL Despite trading at depressed levels @AbCelleraBio Biologics continues to earn Buy ratings from analysts. This article explores why NASDAQ: ABCLs platform pipeline progress and upcoming earnings could challenge the markets https://biotechhealthx.com/biotech-news/heres-why-wall-street-still-says-buy-even-as-abcellera-abcl-trades-like-a-penny-stock/ https://biotechhealthx.com/biotech-news/heres-why-wall-street-still-says-buy-even-as-abcellera-abcl-trades-like-a-penny-stock/"
X Link 2026-02-06T11:30Z [---] followers, [---] engagements
"$AEMD Aethlon Medical (NASDAQ:AEMD) is developing a breakthrough FDA-designated device that removes harmful viruses and cancer-related exosomes directly from the blood. As investors obsess over earnings the real story may be hiding in plain sight. https://biotechhealthx.com/biotech-news/heres-why-you-should-invest-in-aethlon-medical-aemd/ https://biotechhealthx.com/biotech-news/heres-why-you-should-invest-in-aethlon-medical-aemd/"
X Link 2026-02-06T11:30Z [---] followers, [--] engagements
"$DNA @Ginkgo Bioworks Inc. ranks 1st in our list of the Top [--] Biotech Stocks With the Biggest Price Gains Today. The company has moved beyond AI buzzwords by deploying a GPT-5-driven autonomous lab that generated nearly [------] data points. The work suggests AI can meaningfully lower costs and improve productivity in real biological experiments. https://biotechhealthx.com/biotech-news/is-ginkgo-bioworks-dna-a-smart-long-term-pick/ https://biotechhealthx.com/biotech-news/is-ginkgo-bioworks-dna-a-smart-long-term-pick/"
X Link 2026-02-06T11:31Z [---] followers, [---] engagements
"$BHVN @biohaven has big upside potential but biotech risk is real. Heres an objective look at BHVN whats driving interest and what could derail the thesis. https://biotechhealthx.com/biotech-news/heres-what-makes-biohaven-bhvn-a-smart-long-term-buy/ https://biotechhealthx.com/biotech-news/heres-what-makes-biohaven-bhvn-a-smart-long-term-buy/"
X Link 2026-02-08T17:07Z [---] followers, [---] engagements
"$ADMA @AdmaBiologics (NASDAQ:ADMA) emerges as our top biotech stock for February [----] supported by rising profitability expanding plasma supply and strong earnings visibility. https://biotechhealthx.com/biotech-news/adma-biologics-adma-1-biotech-stock-pick-for-february-2026/ https://biotechhealthx.com/biotech-news/adma-biologics-adma-1-biotech-stock-pick-for-february-2026/"
X Link 2026-02-08T17:08Z [---] followers, [---] engagements
"$MBRX $ACHV $AVTX $DBVT $MNMD [----] is packed with Phase [--] results Phase [--] topline data and FDA decision dates that can reprice biotech stocks fast. This watchlist screens NYSE/NASDAQ names under $2B market cap and ranks the top [--] by market capbuilt for investors hunting asymmetric upside. (@achievelifesci @Avalo Therapeutics @DBVTechnologies @MindMedicineAU @moleculinbio) https://biotechhealthx.com/biotech-news/top-5-best-biotech-micro-caps-with-major-clinical-catalysts-in-2026/ https://biotechhealthx.com/biotech-news/top-5-best-biotech-micro-caps-with-major-clinical-catalysts-in-2026/"
X Link 2026-02-12T09:00Z [---] followers, [---] engagements
"$MNMD If youre researching @MindMedicineAU start with the background: a clinical-stage biotech aiming to turn psychedelic-inspired science into scalable psychiatric medicines. We explain the companys pipeline framing trial strategy and what makes it different in mental health biotech. https://biotechhealthx.com/biotech-news/mindmed-mnmd-stock-101-why-this-psychedelic-biotech-isnt-playing-small-anymore/ https://biotechhealthx.com/biotech-news/mindmed-mnmd-stock-101-why-this-psychedelic-biotech-isnt-playing-small-anymore/"
X Link 2026-02-12T17:08Z [---] followers, [--] engagements
"$DBVT Long before exposure management became a buzzword in tech @DBVTechnologies was already chasing exposure in immunologycontrolled micro-exposures through the skin via the VIASKIN platform. Learn the background behind the epicutaneous immunotherapy story driving DBVT stock interest. https://biotechhealthx.com/biotech-news/dbv-technologies-dbvt-didnt-chase-a-fad-it-built-a-category-the-peanut-allergy-patch/ https://biotechhealthx.com/biotech-news/dbv-technologies-dbvt-didnt-chase-a-fad-it-built-a-category-the-peanut-allergy-patch/"
X Link 2026-02-12T17:09Z [---] followers, [--] engagements
"$ACHV @achievelifesci (NASDAQ: ACHV) is chasing one of the biggest public-health markets in biotech: nicotine dependence treatment. Heres why cytisinicline the June [--] [----] PDUFA timeline and a massive quit-smoking opportunity have investors watching closely. https://biotechhealthx.com/biotech-news/achieve-life-sciences-achv-has-a-june-2026-make-or-break-date-is-this-the-smoking-cessation-biotech-everyones-early-on/ https://biotechhealthx.com/biotech-news/achieve-life-sciences-achv-has-a-june-2026-make-or-break-date-is-this-the-smoking-cessation-biotech-everyones-early-on/"
X Link 2026-02-12T17:10Z [---] followers, [--] engagements
"$MBRX Anthracycline cardiotoxicity is one of oncologys biggest tradeoffs. @moleculinbio is pushing Annamycin as a potential non-cardiotoxic anthracycline for relapsed or refractory AML. Learn what the MIRACLE Phase [--] trial means for MBRX stock and why safety narratives can re-rate biotech stocks fast. https://biotechhealthx.com/biotech-news/the-no-heart-damage-cancer-drug-angle-is-moleculin-mbrxs-annamycin-the-plot-twist-in-aml/ https://biotechhealthx.com/biotech-news/the-no-heart-damage-cancer-drug-angle-is-moleculin-mbrxs-annamycin-the-plot-twist-in-aml/"
X Link 2026-02-12T17:10Z [---] followers, [--] engagements
"$NUVB @nuvationbioinc (NYSE: NUVB) is no longer just a clinical-stage storyits FDA-approved oncology launch is producing trackable momentum with patient starts stacking quarter after quarter. Heres why that matters for precision oncology investors hunting [----] biotech catalysts. https://biotechhealthx.com/biotech-news/nuvation-nuvbs-quiet-launch-isnt-quiet-anymore-the-patient-start-numbers-that-got-biotech-watching/ https://biotechhealthx.com/biotech-news/nuvation-nuvbs-quiet-launch-isnt-quiet-anymore-the-patient-start-numbers-that-got-biotech-watching/"
X Link 2026-02-14T04:14Z [---] followers, [--] engagements
"$CMPX Compass Therapeutics Inc. (NASDAQ: CMPX) has randomized Phase 2/3 traction in aggressive biliary tract cancer and a near-term PFS/OS moment that can re-rate the story fast. With a roughly $1.12B market cap and a runway narrative that reduces dilution fear CMPX is one of the more catalyst-loaded oncology biotech stocks to watch in [----]. https://biotechhealthx.com/biotech-news/compass-therapeutics-cmpx-has-a-survival-data-trapdoor-and-2026-might-be-when-it-opens/ https://biotechhealthx.com/biotech-news/compass-therapeutics-cmpx-has-a-survival-data-trapdoor-and-2026-might-be-when-it-opens/"
X Link 2026-02-14T04:15Z [---] followers, [--] engagements
"$VSTM @VerastemOncolog (NASDAQ: VSTM) has already crossed the line most biotech stocks never reach: an FDA-approved precision oncology launch with real net product revenue momentum. Heres why the [----] setupcommercial execution KRAS-mutated LGSOC focus and RAS/MAPK pipeline optionalitycould trigger a serious re-rating if adoption keeps climbing. https://biotechhealthx.com/biotech-news/verastem-vstm-isnt-small-cap-roulette-anymore-its-a-commercial-oncology-ramp-with-a-2026-twist/"
X Link 2026-02-14T04:17Z [---] followers, [--] engagements
"$ALLO Investors searching ALLO stock and allogeneic CAR T are hunting one answer: can off-the-shelf CAR-T become routine medicine This deep dive frames the bullish thesis around ALPHA3 MRD clearance in large B-cell lymphoma ALLO-329 in autoimmune disease and the manufacturing scale argument that could turn @AllogeneTx from a niche bet into a category trade. https://biotechhealthx.com/biotech-news/the-market-cap-is-small-the-idea-is-huge-can-allogene-allo-make-car-t-as-easy-as-ordering-a-drug/"
X Link 2026-02-14T04:17Z [---] followers, [--] engagements
"$CADL Candel Therapeutics Inc. (NASDAQ:CADL) is one of those small-caps that can flip the narrative fastbecause its not pitching theory. Its lead program has reported Phase [--] prostate cancer results with a statistically significant endpoint win and the company is pointing to a clear regulatory runway that investors can actually calendar. https://biotechhealthx.com/biotech-news/the-290m-cancer-biotech-with-phase-3-proof-candel-cadls-viral-immunotherapy-isnt-just-a-science-fair-anymore/"
X Link 2026-02-14T04:32Z [---] followers, [---] engagements
"$CNTX Context Therapeutics Inc. (NASDAQ: CNTX) did what most small-cap biotechs wontkilled the old story and rebuilt around T cell engager bispecific antibodies for solid tumors. With a $223.27M market cap and leverage at 30.90% CNTX is a classic platform re-rating candidate heading into [----] oncology catalysts and Phase [--] data updates. https://biotechhealthx.com/biotech-news/context-cntxs-glow-up-from-old-thesis-to-t-cell-engager-chaos-in-a-good-way/ https://biotechhealthx.com/biotech-news/context-cntxs-glow-up-from-old-thesis-to-t-cell-engager-chaos-in-a-good-way/"
X Link 2026-02-14T04:33Z [---] followers, [---] engagements
"$NKTX @nkartatx (NASDAQ: NKTX) isnt chasing crowded oncology anymoreits aiming at B celldriven autoimmune disease with an off-the-shelf CAR-NK therapy. Heres why the pivot matters what immune reset could mean for patients and why [----] data could flip the NKTX narrative fast. https://biotechhealthx.com/biotech-news/nkarta-nktxs-plot-twist-from-cancer-chaos-to-autoimmune-immune-reset-hype/ https://biotechhealthx.com/biotech-news/nkarta-nktxs-plot-twist-from-cancer-chaos-to-autoimmune-immune-reset-hype/"
X Link 2026-02-14T04:34Z [---] followers, [--] engagements
"$ONCY @Oncolytics (NASDAQ: ONCY) is pitching pelareorep as a systemically delivered oncolytic virus immunotherapy that can boost chemo and checkpoint results. This deep dive explains why [----] could be a major re-rating windowif the company proves a credible registration path and partnership traction. https://biotechhealthx.com/biotech-news/oncolytics-oncy-is-a-90m-science-vs-reality-fight-and-2026-is-when-pelareorep-has-to-win/ https://biotechhealthx.com/biotech-news/oncolytics-oncy-is-a-90m-science-vs-reality-fight-and-2026-is-when-pelareorep-has-to-win/"
X Link 2026-02-14T04:34Z [---] followers, [---] engagements
"$PMVP Searching PMVP stock forecast or PMV Pharmaceuticals pipeline Heres the bull case investors are watching: an oral mutation-specific p53 reactivator with tumor-agnostic upside and an ovarian cancer center of gravity. If response rates and duration hold up PMVP can shift from science story to real pathway storywhere micro-caps often reprice violently. https://biotechhealthx.com/biotech-news/pmv-pharmaceuticals-pmvp-forecast-2026-one-mutation-one-oral-drug-and-a-re-rating-that-could-hit-fast/"
X Link 2026-02-14T04:35Z [---] followers, [--] engagements
"$IMMX @Immixbiopharma's BCMA-targeted CAR-T treatment NXC-201 is emerging as a major contender in relapsed/refractory AL amyloidosis. Discover why analysts see IMMX as a rising biotech with strong science regulatory momentum and a breakthrough-ready immunotherapy platform. https://biotechhealthx.com/biotech-news/immix-biopharma-immx-surges-in-rare-disease-innovation-with-breakthrough-al-amyloidosis-therapy/ https://twitter.com/i/web/status/1999084688887927019"
X Link 2025-12-11T11:51Z [---] followers, [---] engagements
"$EWTX Wall Street analysts have issued mixed but generally positive views on @EdgewiseTx as its lead drug advances through clinical development for dystrophinopathies. https://biotechhealthx.com/biotech-news/heres-why-analysts-keep-raising-targets-on-edgewise-therapeutics-ewtx/ https://biotechhealthx.com/biotech-news/heres-why-analysts-keep-raising-targets-on-edgewise-therapeutics-ewtx/"
X Link 2025-12-13T23:20Z [---] followers, [---] engagements
"$BIIB @biogen Inc. has spent decades focusing on diseases of the brain and spinal cord building scientific platforms that target protein aggregation RNA splicing and neurodegeneration. https://biotechhealthx.com/biotech-news/how-biogen-inc-biib-built-one-of-biotechs-most-specialized-neuroscience-platforms/ https://biotechhealthx.com/biotech-news/how-biogen-inc-biib-built-one-of-biotechs-most-specialized-neuroscience-platforms/"
X Link 2025-12-13T23:21Z [---] followers, [---] engagements
"$GLSI Unlike traditional oncology drugs Greenwich LifeSciences Inc (NASDAQ:GLSI) is focused on cancer prevention through immunotherapy. Learn how GLSI-100 works why Phase III data matters and what makes this approach different. https://biotechhealthx.com/biotech-news/greenwich-lifesciences-inc-glsi-isnt-treating-cancer-its-trying-to-stop-it-from-coming-back/ https://biotechhealthx.com/biotech-news/greenwich-lifesciences-inc-glsi-isnt-treating-cancer-its-trying-to-stop-it-from-coming-back/"
X Link 2025-12-15T12:35Z [---] followers, [---] engagements
"$ATHA The pivot of the century is here. @athirapharma Inc. (NASDAQ: ATHA) has abandoned its old path to snatch a "ready-to-go" Phase [--] breast cancer drug. With a market opportunity of $15.9 billion see why ATHA stock is no longer a gamble but a strategic "Strong Buy" for the [----] healthcare bull run. https://biotechhealthx.com/biotech-news/forget-alzheimers-athira-pharma-atha-just-found-a-multi-billion-dollar-cure/ https://biotechhealthx.com/biotech-news/forget-alzheimers-athira-pharma-atha-just-found-a-multi-billion-dollar-cure/"
X Link 2025-12-21T16:00Z [---] followers, [--] engagements
"$CADL @Nasdaq - Investors are rushing into Candel Therapeutics Inc. (NASDAQ:CADL) after shocking Phase [--] data revealed survival rates for lung cancer more than doubled historical benchmarks. With a pivotal Phase [--] launch scheduled for Q2 [----] find out why CADL is the "must-watch" stock for anyone tracking the future of immunotherapy and viral oncology on the NASDAQ. https://biotechhealthx.com/biotech-news/the-in-situ-miracle-why-candel-therapeutics-cadl-just-doubled-life-expectancy/"
X Link 2025-12-21T16:01Z [---] followers, [---] engagements
"$HTLQ Heart Test Laboratories Inc (NASDAQ:HTLQ) focuses on early detection of heart disease using AI-enhanced ECGs offering scalable diagnostics for cardiovascular disease prevention and risk assessment. https://biotechhealthx.com/biotech-news/this-ai-cardiac-screening-stock-targets-the-worlds-1-killer-heart-test-laboratories-inc-htlq/ https://biotechhealthx.com/biotech-news/this-ai-cardiac-screening-stock-targets-the-worlds-1-killer-heart-test-laboratories-inc-htlq/"
X Link 2025-12-24T05:09Z [---] followers, [--] engagements
"$KYTX @Kyverna_Tx Therapeutics Inc (NASDAQ:KYTX) raised approximately $100 million to accelerate clinical trials for its lead CAR T therapy strengthening its balance sheet and extending development runway. https://biotechhealthx.com/biotech-news/why-investors-are-watching-kyverna-therapeutics-kytx-after-its-100m-capital-raise/ https://biotechhealthx.com/biotech-news/why-investors-are-watching-kyverna-therapeutics-kytx-after-its-100m-capital-raise/"
X Link 2025-12-24T05:09Z [---] followers, [--] engagements
"$CYBN @CybinInc (NASDAQ: CYBN) is emerging as one of the most talked-about mental health stocks as it advances late-stage psychedelic drug development for major depressive disorder and anxiety signaling a potential shift in how mental healthcare is treated. https://biotechhealthx.com/biotech-news/cybin-cybn-is-quietly-rewriting-the-future-of-mental-healthcare-heres-why-investors-are-paying-attention/ https://biotechhealthx.com/biotech-news/cybin-cybn-is-quietly-rewriting-the-future-of-mental-healthcare-heres-why-investors-are-paying-attention/"
X Link 2025-12-27T23:09Z [---] followers, [---] engagements
"$UPC Universe Pharmaceuticals Inc (NASDAQ:UPC) sells traditional Chinese medicine pieces and cold and flu medications while also distributing third party pharmaceutical products creating a two-category revenue model that some investors believe could reshape fair value. https://biotechhealthx.com/biotech-news/universe-pharmaceuticals-upc-surged-heres-what-investors-should-know-about-its-business-model/ https://biotechhealthx.com/biotech-news/universe-pharmaceuticals-upc-surged-heres-what-investors-should-know-about-its-business-model/"
X Link 2025-12-28T00:11Z [---] followers, [--] engagements
"$UNCY @unicycive Therapeutics Inc (NASDAQ:UNCY) is a clinical-stage biotechnology company developing treatments for kidney diseases led by oxylanthanum carbonate an investigational phosphate binding agent developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Heres why investors are tracking UNCY shares the companys background and the key approval timeline shaping the stock narrative. https://biotechhealthx.com/biotech-news/unicycive-therapeutics-uncy-targets-dialysis-pill-burden-with-a-next-gen-phosphate-binding-agent/"
X Link 2025-12-28T01:00Z [---] followers, [---] engagements
"$ICCC ImmuCell Corporation (NASDAQ:ICCC) develops and manufactures animal health products that improve cattle health and productivity across dairy and beef operations. This background deep dive explains how First Defense became a scours prevention leader why manufacturing equipment and quality matter in animal health and why ICCC is showing up on more Nasdaq watchlists. https://biotechhealthx.com/biotech-news/immucell-corporation-iccc-is-quietly-building-an-animal-health-powerhouse-most-investors-arent-watching-yet/"
X Link 2025-12-28T01:02Z [---] followers, [---] engagements
"$XENE Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is expanding its lead drug beyond epilepsy into major depressive disorder and bipolar depression potentially unlocking a much larger market for its precision neuroscience platform. https://biotechhealthx.com/biotech-news/from-rare-epilepsy-to-mental-health-why-xenon-pharmaceuticals-xene-is-expanding-fast/ https://biotechhealthx.com/biotech-news/from-rare-epilepsy-to-mental-health-why-xenon-pharmaceuticals-xene-is-expanding-fast/"
X Link 2025-12-31T14:11Z [---] followers, [---] engagements
"$UNCY @unicycive Therapeutics Inc. (NASDAQ:UNCY) is developing new treatments for chronic kidney disease and dialysis patients focusing on hyperphosphatemia and real-world patient adherence. Heres why this small biotech company is gaining attention. https://biotechhealthx.com/biotech-news/this-kidney-disease-biotech-is-quietly-targeting-a-billion-dollar-problem-unicycive-therapeutics-uncy-explained/ https://biotechhealthx.com/biotech-news/this-kidney-disease-biotech-is-quietly-targeting-a-billion-dollar-problem-unicycive-therapeutics-uncy-explained/"
X Link 2025-12-31T14:26Z [---] followers, [---] engagements
"$SNSE Learn how Sensei Biotherapeutics Inc (NASDAQ:SNSE) is developing novel antibody therapies and why its immune-modulating pipeline could position it as a future breakout biotech stock. https://biotechhealthx.com/biotech-news/sensei-biotherapeutics-snse-could-become-a-hidden-winner-in-biotech/ https://biotechhealthx.com/biotech-news/sensei-biotherapeutics-snse-could-become-a-hidden-winner-in-biotech/"
X Link 2026-01-01T16:56Z [---] followers, [---] engagements
"$INSP Explore how @InspireMedical Systems (NYSE:INSP) translated neuroscience research into a commercial medical device now used by physicians worldwide. https://biotechhealthx.com/biotech-news/from-research-lab-to-operating-room-the-rise-of-inspire-medical-systems-insp/ https://biotechhealthx.com/biotech-news/from-research-lab-to-operating-room-the-rise-of-inspire-medical-systems-insp/"
X Link 2026-01-01T16:57Z [---] followers, [---] engagements
"$RGNX @REGENXBIO Inc (NASDAQ:RGNX) is a clinical-stage biotechnology company developing gene therapy product candidates with curative potential designed to improve lives for patients and families worldwide. https://biotechhealthx.com/biotech-news/regenxbio-rgnx-might-be-the-most-underrated-name-in-the-gene-therapy-revolution/ https://biotechhealthx.com/biotech-news/regenxbio-rgnx-might-be-the-most-underrated-name-in-the-gene-therapy-revolution/"
X Link 2026-01-04T17:21Z [---] followers, [---] engagements
"$VVOS With FDA-cleared devices a growing network of sleep centers and strong patient preference trends Vivos Therapeutics Inc (NASDAQ:VVOS) may be quietly building one of healthcares most disruptive platforms in airway health. https://biotechhealthx.com/biotech-news/why-some-investors-think-vivos-therapeutics-vvos-could-be-the-next-big-disruptor-in-sleep-medicine/ https://biotechhealthx.com/biotech-news/why-some-investors-think-vivos-therapeutics-vvos-could-be-the-next-big-disruptor-in-sleep-medicine/"
X Link 2026-01-04T17:22Z [---] followers, [---] engagements
"$APGE With new clinical data and a strong balance sheet Apogee Therapeutics (NASDAQ:APGE) is emerging as a compelling biotech story in immunology and inflammation research. https://biotechhealthx.com/biotech-news/heres-why-apogee-therapeutics-apge-is-suddenly-on-the-radar-of-biotech-investors/ https://biotechhealthx.com/biotech-news/heres-why-apogee-therapeutics-apge-is-suddenly-on-the-radar-of-biotech-investors/"
X Link 2026-01-06T14:44Z [---] followers, [---] engagements
"$COEP Coeptis Therapeutics (NASDAQ:COEP) is still in the early stages of development but its focus on cellular immunotherapy could make it one of the most intriguing speculative biotech stocks today. https://biotechhealthx.com/biotech-news/coeptis-therapeutics-coep-is-not-profitable-yet-and-thats-exactly-why-its-interesting/ https://biotechhealthx.com/biotech-news/coeptis-therapeutics-coep-is-not-profitable-yet-and-thats-exactly-why-its-interesting/"
X Link 2026-01-06T14:44Z [---] followers, [--] engagements
"$OSCR From digital care navigation to proactive health management @OscarHealth Inc (NYSE:OSCR) is redefining what insurance can be. Learn how OSCR stock fits into the future of healthcare technology. https://biotechhealthx.com/biotech-news/oscar-health-oscr-isnt-just-an-insurer-its-a-health-tech-platform-in-disguise/ https://biotechhealthx.com/biotech-news/oscar-health-oscr-isnt-just-an-insurer-its-a-health-tech-platform-in-disguise/"
X Link 2026-01-09T05:37Z [---] followers, [---] engagements
"$MRK @Merck & Co. Inc. (NYSE:MRK) combines blockbuster cancer drugs a deep research pipeline and global scale making it one of the most resilient and strategically positioned pharmaceutical companies in the world. https://biotechhealthx.com/biotech-news/why-merck-co-mrk-could-be-the-safest-growth-stock-in-global-healthcare/ https://biotechhealthx.com/biotech-news/why-merck-co-mrk-could-be-the-safest-growth-stock-in-global-healthcare/"
X Link 2026-01-09T05:40Z [---] followers, [--] engagements
"$LGND Ligand Pharmaceuticals Inc. (NASDAQ:LGND) earns royalties from dozens of drug programs without running clinical trials. Discover how this unusual biotech model works and why investors are curious about it. https://biotechhealthx.com/biotech-news/this-biotech-stock-doesnt-make-drugs-it-makes-money-from-them-ligand-pharmaceuticals-lgnd/ https://biotechhealthx.com/biotech-news/this-biotech-stock-doesnt-make-drugs-it-makes-money-from-them-ligand-pharmaceuticals-lgnd/"
X Link 2026-01-13T16:55Z [---] followers, [--] engagements
"$CVKD Anticoagulation may sound old-school but Cadrenal Therapeutics is modernizing it for todays toughest patients. NASDAQ:CVKD shows how overlooked medical areas can still drive innovation. https://biotechhealthx.com/biotech-news/cadrenal-therapeutics-cvkd-proof-that-boring-medicine-can-be-disruptive/ https://biotechhealthx.com/biotech-news/cadrenal-therapeutics-cvkd-proof-that-boring-medicine-can-be-disruptive/"
X Link 2026-01-18T16:48Z [---] followers, [--] engagements
"$KVUE Defensive stocks arent meant to feel uncomfortable. @kenvue (NYSE:KVUE) is challenging that assumption as risks quietly stack up. https://biotechhealthx.com/biotech-news/kenvue-kvue-was-supposed-to-be-safe-so-why-does-it-feel-risky-now/ https://biotechhealthx.com/biotech-news/kenvue-kvue-was-supposed-to-be-safe-so-why-does-it-feel-risky-now/"
X Link 2026-01-18T16:50Z [---] followers, [--] engagements
"$GPCR Structure Therapeutics Inc. (NASDAQ:GPCR) is betting that oral GPCR drugs can crack massive metabolic markets that are still dominated by injections and supply constraints. https://biotechhealthx.com/biotech-news/structure-therapeutics-gpcr-is-trying-to-do-what-big-pharma-still-hasnt-turn-obesity-drugs-into-pills/ https://biotechhealthx.com/biotech-news/structure-therapeutics-gpcr-is-trying-to-do-what-big-pharma-still-hasnt-turn-obesity-drugs-into-pills/"
X Link 2026-01-18T17:38Z [---] followers, [--] engagements
"$RCEL From burn units to trauma centers @AvitaMedical is redefining wound care with regenerative technology. Discover why NASDAQ:RCEL keeps gaining attention in healthcare investing circles. https://biotechhealthx.com/biotech-news/this-nasdaq-stock-is-turning-skin-healing-into-a-business-meet-avita-medical-rcel/ https://biotechhealthx.com/biotech-news/this-nasdaq-stock-is-turning-skin-healing-into-a-business-meet-avita-medical-rcel/"
X Link 2026-01-18T17:59Z [---] followers, [--] engagements
"$ALEC While critics focus on declining sales forecasts Alector Inc. (NASDAQ: ALEC) is building something far bigger beneath the surface targeting immune pathways in neurodegenerative diseases with asymmetric upside few biotech stocks can match. https://biotechhealthx.com/biotech-news/alector-alec-isnt-chasing-revenue-its-chasing-a-breakthrough-the-market-cant-ignore/ https://biotechhealthx.com/biotech-news/alector-alec-isnt-chasing-revenue-its-chasing-a-breakthrough-the-market-cant-ignore/"
X Link 2026-01-23T17:16Z [---] followers, [--] engagements
"$BLTE @BeliteBio (NASDAQ:BLTE) is emerging as one of the most talked-about retinal disease biotech stocks as its Phase [--] program advances and commercialization plans take shape. Heres why investors are suddenly paying attention. https://biotechhealthx.com/uncategorized/is-belite-bio-blte-quietly-building-a-billion-dollar-future/ https://biotechhealthx.com/uncategorized/is-belite-bio-blte-quietly-building-a-billion-dollar-future/"
X Link 2026-01-25T16:44Z [---] followers, [--] engagements
"$KRYS @KrystalBiotech (NASDAQ:KRYS) has evolved from a niche gene therapy developer into a commercial-stage biotech. With KRYS stock increasingly discussed among @NasdaqExchange biotech investors this background explains the growing interest. https://biotechhealthx.com/biotech-news/why-krystal-biotech-krys-is-becoming-a-name-investors-cant-ignore/ https://biotechhealthx.com/biotech-news/why-krystal-biotech-krys-is-becoming-a-name-investors-cant-ignore/"
X Link 2026-01-25T16:45Z [---] followers, [--] engagements
"$PTCT PTC Therapeutics (NASDAQ:PTCT) has been grinding since [----] long before biotech hype was cool. Heres why this rare disease stock is suddenly catching investor attention. https://biotechhealthx.com/biotech-news/this-biotech-refused-to-quit-for-25-years-now-ptc-therapeutics-ptct-is-getting-its-moment/ https://biotechhealthx.com/biotech-news/this-biotech-refused-to-quit-for-25-years-now-ptc-therapeutics-ptct-is-getting-its-moment/"
X Link 2026-01-25T16:46Z [---] followers, [--] engagements
"$CRNX Not every biotech needs fireworks on day one. @Crinetics (NASDAQ:CRNX) is building steady value in endocrine diseasesand CRNX stock reflects that patience. https://biotechhealthx.com/biotech-news/why-crinetics-pharmaceuticals-crnx-is-the-slow-burn-biotech-investors-love/ https://biotechhealthx.com/biotech-news/why-crinetics-pharmaceuticals-crnx-is-the-slow-burn-biotech-investors-love/"
X Link 2026-01-25T16:46Z [---] followers, [--] engagements
"$COEP From governance missteps to a shifting strategy Coeptis Therapeutics (NASDAQ:COEP) shows many traits investors associate with struggling micro-cap biotechs. https://biotechhealthx.com/biotech-news/this-biotech-keeps-raising-red-flags-why-coeptis-therapeutics-coep-looks-more-like-a-warning-than-an-opportunity/ https://biotechhealthx.com/biotech-news/this-biotech-keeps-raising-red-flags-why-coeptis-therapeutics-coep-looks-more-like-a-warning-than-an-opportunity/"
X Link 2026-01-28T16:38Z [---] followers, [--] engagements
"$GRI GRI Bio Inc. has delivered strong Phase 2a data in idiopathic pulmonary fibrosis while extending its cash runway into [----]. With real clinical proof RNA-sequencing validation and a strengthened balance sheet NASDAQ: GRI may be entering a very different risk category than investors assume. https://biotechhealthx.com/biotech-news/should-you-now-consider-investing-in-gri-bio-gri/ https://biotechhealthx.com/biotech-news/should-you-now-consider-investing-in-gri-bio-gri/"
X Link 2026-02-06T11:25Z [---] followers, [---] engagements
"$GBIO With funding secured through [----] @generationbio has the runway to advance clinical trials without immediate dilution strengthening its bullish case. https://biotechhealthx.com/biotech-news/generation-bio-gbio-has-185m-in-cash-heres-why-that-matters/ https://biotechhealthx.com/biotech-news/generation-bio-gbio-has-185m-in-cash-heres-why-that-matters/"
X Link 2025-08-27T01:57Z [---] followers, [---] engagements
"$OCUL Ocular Therapeutix offers 37.9M shares at $12.53 securing $475M to advance Axpaxli for wet AMD and NPDR in pivotal Phase [--] studies. https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-raises-475m-to-fund-phase-3-axpaxli-trials/ https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-raises-475m-to-fund-phase-3-axpaxli-trials/"
X Link 2025-10-03T08:03Z [---] followers, [---] engagements
"$TTRX Backed by its PermaFusion platform & 57% efficacy data in eczema trials Turn Therapeutics stormed NASDAQ with a 134% post-close rally. https://biotechhealthx.com/biotech-news/turn-therapeutics-ttrxs-nasdaq-debut-sends-stock-up-134/ https://biotechhealthx.com/biotech-news/turn-therapeutics-ttrxs-nasdaq-debut-sends-stock-up-134/"
X Link 2025-10-09T10:44Z [---] followers, [---] engagements
"$BMRN Multiple first-in-class therapies fuel consistent cash flow and long-term value for BioMarin Pharmaceutical. Learn about it more here https://biotechhealthx.com/biotech-news/biomarin-bmrns-rare-disease-portfolio-generates-over-2-4-billion-in-annual-revenue/ https://biotechhealthx.com/biotech-news/biomarin-bmrns-rare-disease-portfolio-generates-over-2-4-billion-in-annual-revenue/"
X Link 2025-10-19T06:11Z [---] followers, [---] engagements
"$VRDN Three major firms issue Buy ratings on Viridian citing breakthrough data de-risked pipeline and 163% upside potential. https://biotechhealthx.com/biotech-news/heres-why-viridian-therapeutics-vrdn-is-a-strong-buy/ https://biotechhealthx.com/biotech-news/heres-why-viridian-therapeutics-vrdn-is-a-strong-buy/"
X Link 2025-11-08T15:49Z [---] followers, [---] engagements
"$ANVS @AnnovisBio (NYSE:ANVS) secured $6M through a 4000000-share direct offering at $1.50 each. With late-stage Alzheimers and Parkinsons trials advancing investors are watching whether ANVS is preparing for a major rebound in [----]. https://biotechhealthx.com/biotech-news/annovis-bio-anvs-raises-6m-at-1-50-share/ https://biotechhealthx.com/biotech-news/annovis-bio-anvs-raises-6m-at-1-50-share/"
X Link 2025-11-21T00:15Z [---] followers, [---] engagements
"$OCUL RBC Capital raised OCULs price target to $24 following exceptional SOL-1 patient retention over 95% and no safety concerns. Ocular Therapeutix is now preparing an NDA for AXPAXLI that could redefine long-acting wet AMD therapy. https://biotechhealthx.com/biotech-news/analysts-boost-target-to-24-as-ocular-therapeutix-ocul-nears-major-catalyst/ https://biotechhealthx.com/biotech-news/analysts-boost-target-to-24-as-ocular-therapeutix-ocul-nears-major-catalyst/"
X Link 2025-12-06T09:07Z [---] followers, [---] engagements
"$OCUL Ocular Therapeutix Inc (NASDAQ:OCUL) shocked the market with plans to file AXPAXLI using only Phase [--] SOL [--] year-one data. With a stunning 382% three-year return and a 16.4% monthly jump analysts say OCUL remains massively undervalued as the wet AMD market shifts toward long-acting therapy. https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-surges-382-in-3-years/ https://twitter.com/i/web/status/1997979719359484097 https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-surges-382-in-3-years/ https://twitter.com/i/web/status/1997979719359484097"
X Link 2025-12-08T10:41Z [---] followers, [---] engagements
"$AXSM @axsome Therapeutics Inc (NASDAQ:AXSM) is a central nervous system biopharma stock quietly advancing novel treatments for depression narcolepsy and neurological disorders with regulatory momentum and long-term growth potential that could surprise the market. https://biotechhealthx.com/biotech-news/wall-street-isnt-watching-this-cns-stock-yet-but-axsome-therapeutics-axsm-might-be-the-breakout/ https://twitter.com/i/web/status/2006363589645652115 https://biotechhealthx.com/biotech-news/wall-street-isnt-watching-this-cns-stock-yet-but-axsome-therapeutics-axsm-might-be-the-breakout/"
X Link 2025-12-31T13:55Z [---] followers, [--] engagements
"$RVMD Revolution Medicines Inc. (NASDAQ:RVMD) is focused on precision cancer therapies for RAS mutations one of the largest unmet needs in oncology and its progress is starting to reshape investor interest. https://biotechhealthx.com/biotech-news/why-long-term-biotech-investors-are-watching-revolution-medicines-rvmd-closely/ https://biotechhealthx.com/biotech-news/why-long-term-biotech-investors-are-watching-revolution-medicines-rvmd-closely/"
X Link 2026-01-09T05:38Z [---] followers, [---] engagements
"$OCUL Ocular Therapeutix Inc. (NASDAQ:OCUL) is redefining ophthalmology with sustained-release drug delivery that replaces daily eye drops. This deep dive explores why OCUL stock could benefit from long-term shifts in eye care and biotech innovation. https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-is-quietly-changing-how-eye-diseases-are-treated/ https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-is-quietly-changing-how-eye-diseases-are-treated/"
X Link 2026-01-09T05:39Z [---] followers, [---] engagements
"$TECH Hedge funds and institutions dominate @biotechne's shareholder base. We explore why NASDAQ: TECH remains a core holding in long-term life sciences portfolios. https://biotechhealthx.com/biotech-news/nearly-99-institutional-ownership-why-big-money-wont-let-go-of-bio-techne-tech/ https://biotechhealthx.com/biotech-news/nearly-99-institutional-ownership-why-big-money-wont-let-go-of-bio-techne-tech/"
X Link 2026-01-23T17:35Z [---] followers, [--] engagements
"$EYPT Individual investors are stunned as @EyePointPharma Inc. (NASDAQ: EYPT) receives "Strong Buy" upgrades from top-tier firms like TD Cowen and Cantor Fitzgerald. With institutional giants owning 99% of the float find out why DURAVYU is poised to replace monthly eye injections and what the $39 price target means for your [----] portfolio. https://biotechhealthx.com/biotech-news/the-eye-injection-killer-why-eyepoint-eypt-just-triggered-a-massive-strong-buy/ https://biotechhealthx.com/biotech-news/the-eye-injection-killer-why-eyepoint-eypt-just-triggered-a-massive-strong-buy/"
X Link 2025-12-21T16:37Z [---] followers, [---] engagements
"$NAGE With decades of clinical research over [--] issued and pending patents and a market-leading NAD+ product @niagenbio Inc. (NASDAQ:NAGE) is redefining how investors view dietary supplements and bioscience innovation. https://biotechhealthx.com/biotech-news/is-niagen-bioscience-nage-the-best-pure-play-bet-on-nad-and-healthy-aging/ https://biotechhealthx.com/biotech-news/is-niagen-bioscience-nage-the-best-pure-play-bet-on-nad-and-healthy-aging/"
X Link 2025-12-27T23:44Z [---] followers, [---] engagements
"$NAGE @niagenbio (NASDAQ:NAGE) positions itself as research-driven but investors continue to treat it like a consumer supplement stock. https://biotechhealthx.com/biotech-news/niagen-bioscience-nage-wants-to-be-a-health-science-company-the-market-isnt-convinced/ https://biotechhealthx.com/biotech-news/niagen-bioscience-nage-wants-to-be-a-health-science-company-the-market-isnt-convinced/"
X Link 2026-01-18T16:50Z [---] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing